Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Novavax Inc (NVAX)
Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 657,644
  • Shares Outstanding, K 86,305
  • Annual Sales, $ 1,982 M
  • Annual Income, $ -657,940 K
  • 60-Month Beta 1.72
  • Price/Sales 0.34
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NVAX with:

Options Overview Details

View History
  • Implied Volatility 133.56% ( -17.48%)
  • Historical Volatility 104.05%
  • IV Percentile 78%
  • IV Rank 41.00%
  • IV High 193.68% on 03/17/23
  • IV Low 91.79% on 05/26/23
  • Put/Call Vol Ratio 0.74
  • Today's Volume 6,005
  • Volume Avg (30-Day) 17,973
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 283,377
  • Open Int (30-Day) 288,868

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -1.43
  • Number of Estimates 6
  • High Estimate -1.13
  • Low Estimate -1.59
  • Prior Year -6.53
  • Growth Rate Est. (year over year) +78.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.64 +14.76%
on 05/25/23
11.36 -32.92%
on 05/09/23
+0.58 (+8.24%)
since 05/02/23
3-Month
5.61 +35.95%
on 03/23/23
11.36 -32.92%
on 05/09/23
+0.69 (+9.96%)
since 03/02/23
52-Week
5.61 +35.95%
on 03/23/23
76.77 -90.07%
on 07/08/22
-48.35 (-86.39%)
since 06/02/22

Most Recent Stories

More News
Novavax to Participate in the Jefferies Global Healthcare Conference

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will...

NVAX : 7.62 (-1.30%)
Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that...

NVAX : 7.62 (-1.30%)
Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?

These companies haven't given up on the coronavirus vaccine market.

MRNA : 130.51 (+1.55%)
PFE : 38.36 (+0.89%)
NVAX : 7.62 (-1.30%)
OCGN : 0.4724 (+4.58%)
Thinking of Buying Novavax Stock? 3 Numbers You Should Look at First

Has the vaccine-focused biotech become a safer investment?

NVAX : 7.62 (-1.30%)
Wall Street Expects These Unique Stocks to Skyrocket 314% to 943%

Select analysts believe three former high-flying stocks can make their shareholders significantly richer.

NVAX : 7.62 (-1.30%)
CGC : 0.8251 (-1.17%)
PLUG : 8.77 (+3.66%)
Up 40% in 1 Day, Is Novavax Stock a Buy Now?

The market is being a bit too exuberant about the struggling biotech's latest earnings report.

PFE : 38.36 (+0.89%)
NVAX : 7.62 (-1.30%)
Is Novavax Finally Turning Things Around?

Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea

PFE : 38.36 (+0.89%)
MRNA : 130.51 (+1.55%)
NVAX : 7.62 (-1.30%)
JNJ : 156.97 (+1.57%)
Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

Is the biotech on the road to recovery?

MRNA : 130.51 (+1.55%)
PFE : 38.36 (+0.89%)
NVAX : 7.62 (-1.30%)
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the...

NVAX : 7.62 (-1.30%)
Is the Worst Over for Novavax?

Novavax shares climbed 26% in one trading session on the latest cost-cutting news.

NVAX : 7.62 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 8.28
2nd Resistance Point 8.10
1st Resistance Point 7.86
Last Price 7.62
1st Support Level 7.44
2nd Support Level 7.26
3rd Support Level 7.02

See More

52-Week High 76.77
Fibonacci 61.8% 49.58
Fibonacci 50% 41.19
Fibonacci 38.2% 32.79
Last Price 7.62
52-Week Low 5.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar